We have located links that may give you full text access.
Targeting the phosphorylation site of MARCKS alleviates symptoms of steroid-resistant like asthma in a murine model.
British Journal of Pharmacology 2019 Februrary 2
BACKGROUND: Myristoylated alanine-rich C kinase substrate (MARCKS), a protein kinase C (PKC) substrate, facilitates mucus production and neutrophil migration. However, the effects of therapeutic procedures targeting the phosphorylation site of MARCKS on steroid-resistant asthma and the mechanisms underlying such effects have not yet been investigated. We designed a peptide that targets the MARCKS phosphorylation site (MPS peptide) and assessed its therapeutic potential against steroid-resistant asthma.
METHODS: Mice were sensitized with ovalbumin (OVA), alum, and challenged with aerosolized OVA 5 times a week for one month. The mice were intratracheally administered MPS peptides 3 times a week, 1 h before OVA challenge. Asthma symptoms and cell profiles in the bronchoalveolar lavage (BAL) were assessed, and key proteins were analyzed using western blotting.
RESULTS: Phosphorylated (p)-MARCKS was highly expressed in inflammatory and bronchial epithelial cells in OVA-immunized mice. MPS peptide reduced eosinophils, neutrophils, mucus production, collagen deposition, and airway hyper-responsiveness (AHR). Dexamethasone (Dexa) did not alleviate steroid-resistant asthma symptoms. MPS peptide caused a decrease in p-MARCKS, nitrotyrosine and the expression of oxidative stress enzymes, NADPH oxidase dual oxidase 1 (Duox-1) and iNOS, in lung tissues. Compared to Dexa, MPS peptides inhibited C5a production and attenuated interleukin-17A (IL-17A) and KC production in the airway more effectively, thus suppressing asthma symptoms.
CONCLUSIONS: Our findings indicate that targeting MARCKS phosphorylation through MPS treatment may inhibit neutrophilic inflammation and relieves asthma symptoms, thereby highlighting its potential as a therapeutic agent for steroid-resistant asthma.
METHODS: Mice were sensitized with ovalbumin (OVA), alum, and challenged with aerosolized OVA 5 times a week for one month. The mice were intratracheally administered MPS peptides 3 times a week, 1 h before OVA challenge. Asthma symptoms and cell profiles in the bronchoalveolar lavage (BAL) were assessed, and key proteins were analyzed using western blotting.
RESULTS: Phosphorylated (p)-MARCKS was highly expressed in inflammatory and bronchial epithelial cells in OVA-immunized mice. MPS peptide reduced eosinophils, neutrophils, mucus production, collagen deposition, and airway hyper-responsiveness (AHR). Dexamethasone (Dexa) did not alleviate steroid-resistant asthma symptoms. MPS peptide caused a decrease in p-MARCKS, nitrotyrosine and the expression of oxidative stress enzymes, NADPH oxidase dual oxidase 1 (Duox-1) and iNOS, in lung tissues. Compared to Dexa, MPS peptides inhibited C5a production and attenuated interleukin-17A (IL-17A) and KC production in the airway more effectively, thus suppressing asthma symptoms.
CONCLUSIONS: Our findings indicate that targeting MARCKS phosphorylation through MPS treatment may inhibit neutrophilic inflammation and relieves asthma symptoms, thereby highlighting its potential as a therapeutic agent for steroid-resistant asthma.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app